Evidence map›Paper›PMID 27877087›Full record

Trial reportInternational journal of biological sciences2016

IL28B SNP rs12979860 is the Critical Predictor for Sustained Viral Response in Chinese Children Aged 1 to 6 Years with Chronic Hepatitis C.

Yan-Wei Zhong, Hong-Fei Zhang, Yan-Min Shi, Yong-Li Li, Fang Chu, Zhi-Qiang Xu, Da-Wei Chen, Yu Gan, Fu-Chuan Wang, Mei-Lei Gu and 6 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of biological sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Yan-Wei ZhongInstitute of Infectious Diseases, pediatric liver disease therapy and research center, Xisihuan mid-road No.100, Beijing 302 Hospital, Beijing, China.
Hong-Fei ZhangInstitute of Infectious Diseases, pediatric liver disease therapy and research center, Xisihuan mid-road No.100, Beijing 302 Hospital, Beijing, China.
Yan-Min ShiHeBei North University, Changqing road No.36, Zhangjiakou, China.
Yong-Li LiInstitute of Infectious Diseases, pediatric liver disease therapy and research center, Xisihuan mid-road No.100, Beijing 302 Hospital, Beijing, China.
Fang ChuInstitute of Infectious Diseases, pediatric liver disease therapy and research center, Xisihuan mid-road No.100, Beijing 302 Hospital, Beijing, China.
Zhi-Qiang XuInstitute of Infectious Diseases, pediatric liver disease therapy and research center, Xisihuan mid-road No.100, Beijing 302 Hospital, Beijing, China.
Da-Wei ChenInstitute of Infectious Diseases, pediatric liver disease therapy and research center, Xisihuan mid-road No.100, Beijing 302 Hospital, Beijing, China.
Yu GanInstitute of Infectious Diseases, pediatric liver disease therapy and research center, Xisihuan mid-road No.100, Beijing 302 Hospital, Beijing, China.
Fu-Chuan WangInstitute of Infectious Diseases, pediatric liver disease therapy and research center, Xisihuan mid-road No.100, Beijing 302 Hospital, Beijing, China.
Mei-Lei GuInstitute of Infectious Diseases, pediatric liver disease therapy and research center, Xisihuan mid-road No.100, Beijing 302 Hospital, Beijing, China.
Yi DongInstitute of Infectious Diseases, pediatric liver disease therapy and research center, Xisihuan mid-road No.100, Beijing 302 Hospital, Beijing, China.
Shi-Shu ZhuInstitute of Infectious Diseases, pediatric liver disease therapy and research center, Xisihuan mid-road No.100, Beijing 302 Hospital, Beijing, China.
Ce ShiInstitute of Infectious Diseases, pediatric liver disease therapy and research center, Xisihuan mid-road No.100, Beijing 302 Hospital, Beijing, China.
Hua-Hao FanInstitute of Infectious Diseases, pediatric liver disease therapy and research center, Xisihuan mid-road No.100, Beijing 302 Hospital, Beijing, China.
Xiu-Chang ZhangHeBei North University, Changqing road No.36, Zhangjiakou, China.
Min ZhangInstitute of Infectious Diseases, pediatric liver disease therapy and research center, Xisihuan mid-road No.100, Beijing 302 Hospital, Beijing, China.
302 Military Hospital of China · CNHebei North University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical data on children with chronic hepatitis C (CHC) remain extremely limited. This study investigated sustained virologic response (SVR) to alfa-interferon 2b plus RBV treatment in children aged 1-6 years with unsafe injection-acquired CHC. 154 children with CHC aged 1 to 6 years were enrolled, 101 of them were male (65.6%) and 53 were female (34.4%), and they were treated with alfa-interferon at a dose of 1-5 MIU/m

Indexed as

Sustained Virologic ResponseAntiviral AgentsChildChild, PreschoolFemaleGenotypeHepatitis C, ChronicHumansInfantInterferon-alphaInterferon LambdaInterferonsInterleukinsMalePolymorphism, Single NucleotideViral LoadAntiviral AgentsInterferon-alphaInterferon Lambdainterferon-lambda, humanInterferonsInterleukinschronic hepatitis CIL-28B rs12979860

Identifiers

PMID27877087
PMCPMC5118781
OpenAlexW2550806254

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.